Company profile
NERVGEN PHARMA CORP.
NASDAQ:NGENBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05308953 | phase1 | completed | 2021-05-06 | 2023-06-04 | NervGen Pharma | A Phase I Safety Study of NVG-291 in Healthy Adults |
| NCT07799532 | phase3 | not_yet_recruiting | 2026-09-23 | 2027-07-14 | NervGen Pharma | A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury |
| NCT05965700 | phase1_2 | completed | 2023-08-08 | 2025-12-31 | NervGen Pharma | NVG-291 in Spinal Cord Injury Subjects |
FDA applications (0)
No records yet.